Healthpeak Properties cited a decrease in gains on sales of real estate, a decrease in Adjusted NOI from its outpatient medical and lab segments, an increase in loan loss reserves, and an increase in transaction costs as factors for the decrease in net income applicable to common shares for the 3 months ended June 30, 2025.

1. 01

   Healthpeak Properties cited a decrease in gains on sales of real estate, a decrease in Adjusted NOI from its outpatient medical and lab segments, an increase in loan loss reserves, and an increase in transaction costs as factors for the decrease in net income applicable to common shares for the 3 months ended June 30, 2025.

2. 02

   The company cited a decrease in gains on sales of real estate, a decrease in gain upon change of control related to the sale of a 65% interest in lab buildings in San Diego, California, and an increase in depreciation and interest expense as factors for the decrease in net income for the 6 months ended June 30, 2025. It added that an increase in interest income and an increase in Adjusted NOI from its CCRC segment partially offset the decrease.

3. 03

   Healthpeak Properties said that as of June 30, 2025, principal debt-related cash requirements increased by $325 million compared to December 31, 2024, reaching $9 billion. The company said the increase reflected the issuance of $500 million aggregate principal amount of 5.38% senior unsecured notes and an increase in commercial paper of $625 million, partially offset by the repayment of $452 million and $348 million aggregate principal amounts of senior unsecured notes.

4. 04

   Healthpeak Properties said net cash provided by operating activities for the 6 months ended June 30, 2025 increased by $174 million compared to the prior-year period. The company also disclosed that in February 2025 the board increased the quarterly cash dividend per common share from $0.300 to $0.305, resulting in an annualized rate of $1.220.

Key figures

Quarter ended June 30, 2025

Revenue

$694M

Net income

$32M

EPS

$0.05

Analysis scope · Management's discussion (MD&A)We analyzed excerpts of the Management's Discussion and Analysis (MD&A) section (with omissions). Other sections of the report, such as the notes to the financial statements and risk factors, were not reviewed.

AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.

Original filing

The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.